ArticleOncoTargets and therapy2026
Primary Hepatic Epithelioid Gastrointestinal Stromal Tumor: A Rare Case.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary hepatic epithelioid gastrointestinal stromal tumor (GIST) is an extremely rare neoplasm. Due to its non‑specific clinical and radiologic features, it is frequently misdiagnosed as other primary or metastatic hepatic malignancies. Here, we report the case of an 85‑year‑old asymptomatic woman in whom a mass in the left hepatic lobe was incidentally identified during routine examination. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography‑CT revealed a well‑defined malignant lesion in the left hepatic lobe without evidence of extrahepatic disease. The patient underwent neoadjuvant transarterial chemoembolization (TACE), followed by left hemihepatectomy one month later. Histopathologic and immunohistochemical analyses confirmed a high‑risk epithelioid GIST. Adjuvant therapy with oral imatinib (400 mg/day) was initiated six weeks postoperatively. At the 10‑month follow‑up, the patient remained free of tumor recurrence. Despite preoperative diagnostic challenges, the combination of neoadjuvant TACE, curative surgical resection, and adjuvant imatinib resulted in favorable short‑term outcomes in this patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.